Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • After 12 years of...

    After 12 years of service, Lupin Chief Financial Officer quits to pursue non pharma opportunities

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-11-28T16:27:14+05:30  |  Updated On 28 Nov 2018 4:27 PM IST
    After 12 years of service, Lupin Chief Financial Officer quits to pursue non pharma opportunities
    Mumbai: Through a recent release, pharma major Lupin announced the exit of its Chief Financial Officer, Ramesh Swaminathan. The company said in a statement to the exchange informed that the CFO has quit the company to pursue opportunities outside the pharmaceutical industry.

    “We wish to inform that Ramesh Swaminathan, Chief Financial Officer of the Company has decided to pursue other responsibilities outside the pharmaceutical industry and will be leaving the organization in the month of December 2018,” Lupin said in a statement.

    Swaminathan had joined the company in August 2007 and had served the company for twelve long years. He was the executive director of the company. He received the best CFO award for the financial year 2016-2017. He has been credited to the major force behind some of the major financial deals and strategic acquisition for the company in the last decade.

    Moneycontrol reports that he was instrumental in helping the company to grow from sales of Rs 2773 crore in FY08 to Rs 15560 crore in FY18.

    "We thank him for his contributions to Lupin over the last 12 years and wish him success in his future
    endeavours," said Lupin in the statement to the stock exchange.

    Headquartered in Mumbai Lupin is among one of the top five generic drug makers in India.

    The company is yet to announce a replacement for Swaminathan.

    Also Read: Lupin, BC Partners shortlisted for Bayers 1.1 bn dollar dermatology business
    CFOchiefexitsfinancial officerindustryLupinopportunitiespharmaquitsRamesh Swaminathan
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok